Biotech Series C Investors & VC Firms
600 firms in this list, with a median first check of $1M. 112 of them lead rounds. Generated from verified public data and updated continuously.
AN Venture Partners
TokyoPre-Seed–Growth
21 people
Thorney Investment Group
MelbourneSeed–Late Stage
23 people
Delos Capital
CambridgeSeed–Late Stage
12 people
Prime Partners
TokyoPre-Seed–Growth
Asahi Kasei Corporate Venture Capital
Menlo ParkPre-Seed–Late Stage$500K – $3M
19 people
Vensana Capital
MinneapolisSeries A–Late Stage
13 people
SQN Venture Partners, LLC
CharlestonSeed–Late Stage
7 people
NovaCapital
Seed–Late Stage
9 people
Bioqube Ventures
BrusselsPre-Seed–Late Stage$108K – $6.5M
19 people
Bonitás Ventures
BudapestSeries A–Late Stage$540K – $4.3M
19 people
WELL Ventures
VancouverSeed–Growth
16 people
Sonder Capital
San CarlosPre-Seed–Late Stage
15 people
LYFE Capital
Menlo ParkSeed–Late Stage
17 people
New Science Ventures
GreenwichSeed–Late Stage$2M – $8M
7 people
CTI Life Sciences Fund L.P.
MontréalSeed–Late Stage
9 people
Cowin Capital Group
ShenzhenSeed–Late Stage$1.4M – $50M
11 people
Waseda University Ventures
TokyoPre-Seed–Growth
8 people
America's Frontier Fund
ArlingtonPre-Seed–Growth$500K – $10M
13 people
IDG Capital Vietnam
HanoiSeed–Late Stage$250K – $3M
13 people
Enterprise Investors Sp. z o. o.
WarsawSeries A–Growth$21.6M – $81M
24 people
Grazia Equity GmbH
StuttgartSeed–Late Stage$540K – $2.7M
8 people
Kobe University Capital
KobePre-Seed–Growth
10 people
DNA Capital
São PauloPre-Seed–Late Stage$100K – $5M
15 people
Xeraya Capital
Kuala LumpurSeed–Growth
20 people
Related lists
Series C Investors & VC Firms (2751)Biotech Investors & VC Firms (2107)Biotech Seed Investors & VC Firms (1754)Biotech Series A Investors & VC Firms (1596)Biotech Investors & VC Firms in United States (1039)Series C Investors & VC Firms in United States (946)Biotech Series B Investors & VC Firms (900)Series C Investors & VC Firms in Global (896)Biotech Pre-Seed Investors & VC Firms (896)Healthtech Series C Investors & VC Firms (771)
Data sourced from public filings and firms' own websites — see our methodology.


































































